CD4 and tuberculosis: There was a significant proportion of patients who were misclassified by Visitect CD4 LFA (in Phase 1 and 2 of the study) as having CD4 less than 200 cells/mm3 (147/1141; 12.9%) and this could trigger potential ‘over-use’ of CrAg and urine TB LAM tests.